Pharmaceuticals Industry Trends Italy - 2022

Market Monitor

  • Italien
  • Kemi og medicinalvarer

15 Mar 2022

High days sales outstanding in the wholesalers segment

IT Italy pharma credit risk 2022

Italy´s pharmaceuticals industry accounts for about 2% of global production, with 85% of production exported. In general, Italian drug producers record high margins, but since H2 of 2021 they are being affected by a sharp increase in energy prices. Margins of wholesalers and distributors are generally tight, due to high transport costs, discounts to customers and outstanding receivables. On top, there is a 3% margin cap for sales of prescription drugs in the Italian market. Pharmacies try to compensate this with sales of supplements and cosmetic products.

IT Italy pharma output 2022

In Italy, public healthcare expenditure per capita amounts to EUR 280, 30% less than the EU average. While healthcare spending growth will be rather modest in 2022 and 2023, mid-and long-term demand will be driven by demographic developments. The ageing population in Italy will trigger an increase in medical treatments, in particular for chronic diseases.

In general, pharmaceutical producers are well capitalised and not highly geared. In contrast, capitalisation of wholesalers is often low and coupled with high indebtedness, high working capital requirements and steady investments in warehouses across the country, and related logistics. In this segment days sales outstanding (DSO) and days of inventory outstanding (DIO) are rather high and businesses require bank loans in order to compensate slow payments from their customers. It helps that banks are generally willing to provide loans to all subsectors, including this segment. The main reason is that pharmaceuticals is performing better than other Italian industries, with a history of low default rates. We expect that both non-payment notifications and insolvencies will remain low in 2022.

Our underwriting stance is very open for drug producers, due to low gearing, high margins and strong export performance. We have a prudent approach for wholesalers/distributors, in particular for businesses in cooperatives, as their solvency is dependent on the timely payment of their affiliates (pharmacies). The same accounts for pharmacies, due to strong competition from hospitals and para-pharmacies, which puts pressure on their margins.

Relaterede dokumenter

Ansvarsfraskrivelse

Oplysningerne heri er udelukkende informative og må ikke bruges til andre formål. Se venligst den aktuelle police eller den relevante produkt- eller serviceaftale for de gældende betingelser. Intet heri medfører nogen rettighed, forpligtelse eller ansvar på vegne af Atradius, herunder enhver forpligtelse til at foretage due diligence af købere eller på dine vegne. Hvis Atradius foretager en due diligence vedr. en køber, er det for egne forsikringstekniske formål og ikke til fordel for den forsikrede eller nogen anden person. Ydermere må Atradius eller dets tilknyttede virksomheder eller datterselskaber ikke på noget tidspunkt være ansvarlig for direkte, indirekte, konkret dokumenterede tab eller følgetab, der måtte opstå som følge af brugen af udtalelserne i denne information